Actualités

CLS, CBOE, and CNC it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 29, 2026.

Centene (NYSE:CNC) has appointed Lauren M. Tyler to its Board of Directors. Tyler brings leadership experience from major financial institutions, including roles in investment banking, private equity, corporate audit, investor relations, and human capital strategy. Her background includes senior positions at JPMorgan Chase & Co. and board service across several organizations. For investors tracking Centene, the board appointment comes at a time when the stock trades around $65.73, with the...

CBOE, CNC and CRDO made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 25th, 2026.

Incoming board member Lauren Tyler has more than 30 years of leadership experience in the finance world, which could help Centene navigate the challenging operating environment facing insurers.

Centene (CNC) is seeing clear early signs of recovery this year after a disruptive 2025, RBC Capital

Pre-Market Stock Futures: Futures are trading lower after a mixed start to trading on Monday, following the holiday-shortened week due to the Juneteenth Federal holiday. We may start to see some end-of-the-quarter reallocations and selling for Hedge funds, ETFs, and Mutual Funds this week, and today looks like a starting point. With most corporate buybacks ... Here Are Tuesday’s Best Wall Street Analyst Research Calls: Centene, Darden Restaurants, Flutter Entertainment, GE Healthcare, IBM, Nike,

Medical stocks Centene, DaVita and BrightSpring are gaining attention as healthcare tailwinds and market optimism support growth.

CBOE, CNC and CRDO made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 23rd, 2026.

A Healthcare Company Delivering Eye-catching Earnings Surprises and a Renewable Energy Company That's a Big Winner in AI Datacenter Buildout.

Medical stocks like Centene, DaVita and BrightSpring could rally as SpaceX IPO-fueled market optimism lifts broader sector sentiment.

Centene (CNC) has drawn fresh attention after launching a voluntary buyout program for most employees, in response to a substantial drop in health plan membership tied to expiring federal pandemic subsidies and higher consumer costs. See our latest analysis for Centene. At a share price of $61.02, Centene has seen a 77.38% 90 day share price return and a 46.05% year to date share price return, while the 5 year total shareholder return has declined 17.43%. This suggests strong recent momentum...

In recent days, Centene offered voluntary buyouts to most of its roughly 61,000 employees after experiencing significant membership declines in its Affordable Care Act and Medicaid health plans. This workforce move, coupled with broader cost-cutting efforts, underscores how shifts in government-backed coverage can quickly reshape a major insurer’s operating footprint and priorities. We’ll now examine how offering broad voluntary employee buyouts to cut costs may influence Centene’s...

Centene (NYSE:CNC) has launched a wide-scale voluntary separation program, offering buyouts to most of its roughly 61,000 employees. The move comes as the company faces sharp health plan membership declines, particularly in its Medicaid and Affordable Care Act businesses. Centene has indicated that layoffs could follow if voluntary exits do not meet internal targets. The program is unfolding against a backdrop of major workforce restructuring and evolving regulatory and eligibility...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

For the past few years, U.S. health insurers and their investors were hit from every direction. Patients flooded back to seek treatments after the pandemic, and Washington tightened the rules on Medicare Advantage. Medical costs are rising less than feared, the Trump administration has turned more generous, and the once-shunned sector is bouncing back.

In an email to staff Monday, Centene said most employees would be eligible for a voluntary separation program, but would have to decide whether to opt in by July 2.

Long before the stock surged, the company had been openly broadcasting its decision to choose profit over scale. The market initially ignored the signal - until the turnaround became undeniable.

Most of Centene’s 61,000 employees will be eligible to apply for voluntary separation. But the program doesn’t amount to a complete overhaul of the company, a spokesperson said.

Healthcare stocks declined late Monday afternoon with the NYSE Healthcare Index decreasing 0.6% and

Centene has been on fire lately. In the past six months alone, the company’s stock price has rocketed 60.4%, reaching $64.89 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

According to a Bloomberg report, a Centene spokesperson confirmed the company is offering voluntary buyouts to most staff as part of a cost-cutting effort.

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

Molina Healthcare secures an Illinois Medicaid managed care contract starting in 2027, reinforcing its position in a key market and supporting long-term growth.

Centene (NYSE:CNC) has committed US$10 million to expand the Community Care Campus Long Beach, supporting individuals experiencing homelessness through facility upgrades and program funding. The Centene Foundation has also launched a new US$750,000 grant program in Missouri to address social drivers of health across the state. These initiatives extend Centene’s activity beyond its core managed Medicaid and Medicare operations into broader community health and housing support. For you as an...

Ensign Group is riding on rising occupancy, acquisitions and real estate growth, with strong cash flow and low debt supporting long-term expansion.

Barclays upgraded its rating of Oscar to overweight, a buy equivalent, and reiterated its overweight rating on Centene in a new research note.

Centene's margin recovery, cash-flow surge and rising earnings estimates fuel a sharp rebound as Zacks names it Bull of the Day.

Recovering margins, surging cash flow, and upward earnings estimate revisions have this stock back to 52-week highs.

As Centene has notably outperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.

The state said it intends to divvy out new contracts, which represent tens of billions of dollars in revenue for each awardee, to six insurers. Winners are mostly incumbents, except for Humana.